|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PPIL3 |
Gene summary for PPIL3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PPIL3 | Gene ID | 53938 |
| Gene name | peptidylprolyl isomerase like 3 | |
| Gene Alias | CYPJ | |
| Cytomap | 2q33.1 | |
| Gene Type | protein-coding | GO ID | GO:0000375 | UniProtAcc | A0A0S2Z5A8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 53938 | PPIL3 | LZE4T | Human | Esophagus | ESCC | 3.66e-11 | 1.71e-01 | 0.0811 |
| 53938 | PPIL3 | LZE5T | Human | Esophagus | ESCC | 6.73e-03 | 1.90e-01 | 0.0514 |
| 53938 | PPIL3 | LZE7T | Human | Esophagus | ESCC | 3.81e-04 | 2.33e-01 | 0.0667 |
| 53938 | PPIL3 | LZE20T | Human | Esophagus | ESCC | 5.56e-04 | 5.73e-02 | 0.0662 |
| 53938 | PPIL3 | LZE24T | Human | Esophagus | ESCC | 2.07e-12 | 2.67e-01 | 0.0596 |
| 53938 | PPIL3 | LZE6T | Human | Esophagus | ESCC | 1.09e-08 | 2.50e-01 | 0.0845 |
| 53938 | PPIL3 | P2T-E | Human | Esophagus | ESCC | 3.52e-18 | 3.38e-01 | 0.1177 |
| 53938 | PPIL3 | P4T-E | Human | Esophagus | ESCC | 1.71e-27 | 7.64e-01 | 0.1323 |
| 53938 | PPIL3 | P5T-E | Human | Esophagus | ESCC | 1.30e-04 | 1.19e-01 | 0.1327 |
| 53938 | PPIL3 | P8T-E | Human | Esophagus | ESCC | 6.78e-11 | 2.53e-01 | 0.0889 |
| 53938 | PPIL3 | P9T-E | Human | Esophagus | ESCC | 2.47e-09 | 2.38e-01 | 0.1131 |
| 53938 | PPIL3 | P10T-E | Human | Esophagus | ESCC | 6.76e-17 | 3.17e-01 | 0.116 |
| 53938 | PPIL3 | P11T-E | Human | Esophagus | ESCC | 3.27e-13 | 4.55e-01 | 0.1426 |
| 53938 | PPIL3 | P12T-E | Human | Esophagus | ESCC | 4.34e-21 | 4.39e-01 | 0.1122 |
| 53938 | PPIL3 | P15T-E | Human | Esophagus | ESCC | 2.87e-25 | 3.02e-01 | 0.1149 |
| 53938 | PPIL3 | P16T-E | Human | Esophagus | ESCC | 6.78e-18 | 2.70e-01 | 0.1153 |
| 53938 | PPIL3 | P17T-E | Human | Esophagus | ESCC | 3.92e-02 | 2.40e-01 | 0.1278 |
| 53938 | PPIL3 | P20T-E | Human | Esophagus | ESCC | 7.64e-19 | 3.85e-01 | 0.1124 |
| 53938 | PPIL3 | P21T-E | Human | Esophagus | ESCC | 2.24e-21 | 3.47e-01 | 0.1617 |
| 53938 | PPIL3 | P22T-E | Human | Esophagus | ESCC | 2.89e-16 | 2.68e-01 | 0.1236 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0008380111 | Esophagus | ESCC | RNA splicing | 336/8552 | 434/18723 | 1.74e-42 | 3.67e-39 | 336 |
| GO:0000375111 | Esophagus | ESCC | RNA splicing, via transesterification reactions | 248/8552 | 324/18723 | 3.05e-30 | 1.49e-27 | 248 |
| GO:0000377111 | Esophagus | ESCC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 244/8552 | 320/18723 | 2.52e-29 | 1.07e-26 | 244 |
| GO:0000398111 | Esophagus | ESCC | mRNA splicing, via spliceosome | 244/8552 | 320/18723 | 2.52e-29 | 1.07e-26 | 244 |
| GO:0006457110 | Esophagus | ESCC | protein folding | 163/8552 | 212/18723 | 1.13e-20 | 1.74e-18 | 163 |
| GO:001820816 | Esophagus | ESCC | peptidyl-proline modification | 46/8552 | 58/18723 | 1.59e-07 | 2.51e-06 | 46 |
| GO:000041313 | Esophagus | ESCC | protein peptidyl-prolyl isomerization | 32/8552 | 42/18723 | 5.52e-05 | 4.27e-04 | 32 |
| GO:000838020 | Oral cavity | OSCC | RNA splicing | 308/7305 | 434/18723 | 2.43e-42 | 7.70e-39 | 308 |
| GO:000037519 | Oral cavity | OSCC | RNA splicing, via transesterification reactions | 225/7305 | 324/18723 | 5.20e-29 | 2.99e-26 | 225 |
| GO:000037719 | Oral cavity | OSCC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 221/7305 | 320/18723 | 5.50e-28 | 2.18e-25 | 221 |
| GO:000039819 | Oral cavity | OSCC | mRNA splicing, via spliceosome | 221/7305 | 320/18723 | 5.50e-28 | 2.18e-25 | 221 |
| GO:000645718 | Oral cavity | OSCC | protein folding | 154/7305 | 212/18723 | 1.89e-23 | 4.60e-21 | 154 |
| GO:00182088 | Oral cavity | OSCC | peptidyl-proline modification | 42/7305 | 58/18723 | 2.49e-07 | 3.92e-06 | 42 |
| GO:00004134 | Oral cavity | OSCC | protein peptidyl-prolyl isomerization | 28/7305 | 42/18723 | 2.61e-04 | 1.67e-03 | 28 |
| GO:0008380110 | Oral cavity | LP | RNA splicing | 237/4623 | 434/18723 | 1.82e-41 | 3.79e-38 | 237 |
| GO:0000375110 | Oral cavity | LP | RNA splicing, via transesterification reactions | 181/4623 | 324/18723 | 1.36e-33 | 1.70e-30 | 181 |
| GO:0000377110 | Oral cavity | LP | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 179/4623 | 320/18723 | 2.48e-33 | 2.22e-30 | 179 |
| GO:0000398110 | Oral cavity | LP | mRNA splicing, via spliceosome | 179/4623 | 320/18723 | 2.48e-33 | 2.22e-30 | 179 |
| GO:000645719 | Oral cavity | LP | protein folding | 125/4623 | 212/18723 | 1.62e-26 | 8.45e-24 | 125 |
| GO:001820815 | Oral cavity | LP | peptidyl-proline modification | 28/4623 | 58/18723 | 8.35e-05 | 1.07e-03 | 28 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PPIL3 | SNV | Missense_Mutation | c.219N>T | p.Lys73Asn | p.K73N | Q9H2H8 | protein_coding | tolerated(0.28) | benign(0.413) | TCGA-D5-6928-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| PPIL3 | SNV | Missense_Mutation | c.242N>T | p.Glu81Val | p.E81V | Q9H2H8 | protein_coding | deleterious(0.03) | benign(0.036) | TCGA-AG-3592-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| PPIL3 | SNV | Missense_Mutation | c.241N>A | p.Glu81Lys | p.E81K | Q9H2H8 | protein_coding | deleterious(0.04) | benign(0.197) | TCGA-AG-3592-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| PPIL3 | SNV | Missense_Mutation | c.332N>T | p.Lys111Ile | p.K111I | Q9H2H8 | protein_coding | deleterious(0.01) | possibly_damaging(0.856) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| PPIL3 | SNV | Missense_Mutation | rs369410002 | c.466A>G | p.Ile156Val | p.I156V | Q9H2H8 | protein_coding | tolerated(1) | benign(0.001) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PPIL3 | SNV | Missense_Mutation | rs61730410 | c.361N>A | p.Val121Ile | p.V121I | Q9H2H8 | protein_coding | tolerated(0.58) | benign(0.026) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| PPIL3 | SNV | Missense_Mutation | c.307T>G | p.Ser103Ala | p.S103A | Q9H2H8 | protein_coding | deleterious(0.04) | possibly_damaging(0.809) | TCGA-D1-A17Q-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| PPIL3 | SNV | Missense_Mutation | novel | c.485N>A | p.Pro162Gln | p.P162Q | Q9H2H8 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-05-4396-01 | Lung | lung adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
| PPIL3 | SNV | Missense_Mutation | c.318N>A | p.Phe106Leu | p.F106L | Q9H2H8 | protein_coding | deleterious(0) | possibly_damaging(0.68) | TCGA-78-7542-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| PPIL3 | SNV | Missense_Mutation | c.238N>T | p.Ser80Cys | p.S80C | Q9H2H8 | protein_coding | deleterious(0.03) | possibly_damaging(0.748) | TCGA-70-6723-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |